DCPH - Deciphera Pharma announces proposed $150M stock & pre-funded warrants public offering

Deciphera Pharmaceuticals (NASDAQ:DCPH) on Tuesday said it intends to offer and sell $150M of shares and pre-funded warrants to buy shares of its common stock in an underwritten public offering. DCPH stock -5.4% to $9.80 in aftermarket trade. Deciphera also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5M of shares of common stock offered in the public offering. DCPH said it will use a portion of the proceeds to fund development of its cancer therapies vimseltinib and DCC-3116 and to fund the R&D of its pan-RAF program. J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.

For further details see:

Deciphera Pharma announces proposed $150M stock & pre-funded warrants public offering